

## Diabetic Retinopathy Guideline Committee Meeting 6

**Date:** 29<sup>th</sup> November 2022  
**Location:** Virtual Meeting via Zoom  
**Minutes:** Final

<b>Committee members present:</b>		
Mike Burdon (Chair)		Present for all items
John Anderson		Present for all items
Amandeep Bedi		Present for all items
Philip Burgess		Present for all items
Rosalind Creer		Present for all items
Christiana Dinah		Present for all items
Noemi Lois		Present for all items
Diva Shah		Present for all items
Bernadette Warren		Present for all items
Becky Wei Luo		Present for all items

<b>In attendance:</b>		
Mel Anthony E. Acuavera	Medical Officer IV, DOH, Philippines. External observer in partnership with NICE international	Present for all items
Keona Bennett	Administrator, Guideline Development Team	Present for item 1
Nicola Cunliffe	Project Manager, Guideline Development Team	Present for all items
Clare Dadswell	Senior Technical Analyst, Guideline Development Team	Present for all items
Kirsty Luckham	Technical Analyst (Health Economics)	Present for all items
Hugh McGuire	Technical Adviser – NICE International	Present for all items
Syed Mohiuddin	Technical Adviser (Health Economics)	Present for all items
Allandale E. Nacino	Medical Officer IV, DOH, Philippines. External observer in partnership with NICE international	Present for all items
Mark Simmonds	AVID Principal Investigator, Centre for Reviews and Dissemination, University of York	Present for items 1-5
Dan Louie Renz P. Tating	Supervising Health Program Officer, DOH, Philippines. External observer in partnership with NICE international	Present for all items
Hannah Tebbs	Technical Analyst (Health Economics)	Present for all items
Diana Jean V. Vasquez	Medical Officer III, DOH, Philippines. External observer in partnership with NICE international	Present for all items
Ahmed Yousef	Technical Analyst, Guideline Development Team	Present for all items

<b>Apologies:</b>	
Catrina Charlton	Guideline Commissioning Manager, NICE
Yvonne Coalbran	Committee Member
Astrid Aregui	Senior Medical Editor, NICE
Louis Savage	Committee Member
Magdalena Watras	Medicines Lead, NICE
Philip Williams	Resource Impact Lead, NICE
Becky Wei Luo	Committee Member

## **1. Welcome and DOIs for the meeting**

The Chair welcomed the committee members and attendees to the 6th meeting on Diabetic Retinopathy. The committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received, these are noted above.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Diabetic Retinopathy. The Chair asked everyone to verbally declare any new interests that are not listed in the registry. No new interests were declared.

## **2. Presentation on Laser and anti-VEGF for PDR (RQ5)**

The Chair introduced Mark Simmonds, who presented on Laser and anti-VEGF for PDR (RQ5).

## **3. Questions from committee**

The committee had the opportunity to engage and ask questions about the presentation on laser and anti-VEGF for PDR (RQ5).

## **4. Laser and anti-VEGF for PDR (RQ5)**

- **Economic evidence**

The Chair introduced Hannah Tebbs, who presented the health economic evidence on laser and anti-VEGF for PDR (RQ5).

The committee had the opportunity to give feedback and ask questions.

## **5. Discussion of evidence and recommendation drafting (RQ5)**

The committee discussed the evidence presented and the recommendations were drafted for (RQ5).

## **6. Clinical features for stopping or switching (RQ8)**

- **Evidence review**
- **Economic evidence**

Ahmed Yosef and Hannah Tebbs, presented the evidence review and health economic evidence on clinical features for stopping or switching (RQ8).

The committee had the opportunity to give feedback and ask questions.

### **7. Discussion of evidence and recommendation drafting (RQ8)**

The committee discussed the evidence presented and the recommendations were drafted for (RQ8).

### **8. Continued discussion and recommendation drafting (RQ8)**

The committee continued the discussion on the evidence presented and recommendations were drafted for (RQ8).

### **9. AOB, summary and next steps**

The Chair confirmed the next meeting date, next steps and thanked those present for their contributions. The meeting concluded.